Teva Pharmaceuticals
TEVA
772 hedge funds and large institutions have $25B invested in Teva Pharmaceuticals in 2014 Q1 according to their latest regulatory filings, with 120 funds opening new positions, 222 increasing their positions, 325 reducing their positions, and 71 closing their positions.
84% more funds holding in top 10
Funds holding in top 10: 32 → 59 (+27)
70% more call options, than puts
Call options by funds: $1.28B | Put options by funds: $755M
69% more first-time investments, than exits
New positions opened: 120 | Existing positions closed: 71
36% more capital invested
Capital invested by funds: $18.3B → $25B (+$6.67B)
6% more funds holding
Funds holding: 728 → 772 (+44)
1.7% more ownership
Funds ownership: 48.21% → 49.91% (+1.7%)
32% less repeat investments, than reductions
Existing positions increased: 222 | Existing positions reduced: 325
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$813M |
| 2 |
Franklin Resources
San Mateo,
California
|
+$286M |
| 3 |
HCM
Highfields Capital Management
Boston,
Massachusetts
|
+$277M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$202M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$158M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$598M |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
-$233M |
| 3 |
MIP
Mondrian Investment Partners
London,
United Kingdom
|
-$220M |
| 4 |
U
UBS
Zurich,
Switzerland
|
-$202M |
| 5 |
Capital World Investors
Los Angeles,
California
|
-$149M |
TEVA Hedge Fund Activity: Q1 2014 in Review
772 of the 3,475 institutional investors tracked by Wall St. Rank reported a position in Teva Pharmaceuticals (TEVA) for Q1 2014, worth a combined $25B — up 36% from $18.3B a quarter earlier.
Buyers outnumbered sellers: 120 funds opened new TEVA positions and 71 closed out — a net gain of 49 holders — while 222 added to existing stakes and 325 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $813M. The largest seller was Wellington Management Group, cutting an estimated $598M.
- 772 institutional investors held Teva Pharmaceuticals (TEVA) as of Q1 2014, up from 728 in Q4 2013.
- Funds reported $25B of Teva Pharmaceuticals stock for Q1 2014, up 36% quarter-over-quarter.
- 120 funds opened new Teva Pharmaceuticals positions in Q1 2014 and 71 closed out, a net change of +49 holders.
- The largest Teva Pharmaceuticals buyer in Q1 2014 was Fidelity Investments, an estimated $813M added.
- The largest Teva Pharmaceuticals seller in Q1 2014 was Wellington Management Group, an estimated $598M sold.
Based on aggregated 13F filings for Q1 2014.